1. The approach (s), which is/are currently followed to produce human monoclonal antibodies, is/are known as
A.transformation of antigen specific B lymphocytes (EBV)
B.hybridization of 6-thioguanine-resistant human plasmacytoma with immune human lymphocytes
C.combination of EB Vand hybridoma techniques
D.all of these

---

2. Some cross reactions with monoclonal antibodies (MAbs) can occur. Unexpected cross reactions occur more frequently with
A.Ig MAbs
B.IgG
C.IgA
D.IgE

---

3.  Preliminary clinical results with a humanized antibody against the interleukin-2 receptor have suggested the
A.absence of human immune response against murine proteins (HAMA) response
B.presence of HAMA response
C.poor recognition of immunoglobulin, Ig constant regions
D.all of the above

---

4. The cross linkage of antigens by antibodies is known as
A.A. agglutination
B.complement fixation
C.a cross reaction
D.all of these

---

5.  In monoclonal antibody technology, tumor cells that can replicate endlessly are fused with mammalian cells that produce an antibody. The result of this cell fusion is a
A.hybridoma
B.myeloma
C.natural killer cell
D.lymphoblast

---

6. In human B cells and T cells are matured in the
A.bone marrow and thymus respectively
B.bone marrow and thymus respectively
C.bursa and thymus respectively
D.none of these

---

7. An example of mosaic antigen is
A.virus
B.bacteria
C.a hapten
D.protein

---